DDInter1838 DDInter1729
Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Duloxetine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Duloxetine {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Sulindac
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromfenac
Bromfenac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Sulindac
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Deferiprone {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Sulindac
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Cladribine {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Sulindac
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Sulindac
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Sulindac
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Treprostinil
Treprostinil {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) Sulindac
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Sulindac (Compound)
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Sulindac (Compound)
Tositumomab may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Sulindac (Compound)
Tositumomab may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Tositumomab may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Sulindac (Compound)
Tositumomab may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Sulindac (Compound)
Tositumomab may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Sulindac (Compound)
Tositumomab may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil (Compound) binds PPARD (Gene) and Treprostinil (Compound) upregulates PPARD (Gene) and PPARD (Gene) is bound by Sulindac (Compound)